Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Shalby IPO subscribed...

    Shalby IPO subscribed 20 percent on Day 1

    Written by Ruby Khatun Khatun Published On 2017-12-06T10:40:10+05:30  |  Updated On 13 Aug 2021 5:04 PM IST

    New Delhi: The initial public offer of Shalby Ltd, an Ahmedabad-based multi-specialty hospital chain, was subscribed 20% on the first day of the three-day bidding.


    The IPO, which aims to raise Rs 504 crore, received bids for over 29.32 lakh shares against the total issue size of more than 1.45 crore scrips, indicating a subscription of 20%, data available with National Stock Exchange (NSE) showed. The initial share sale of Shalby will be open for public subscriptions until December 7.


    Shalby, yesterday, raised over Rs150 crore from anchor investors.


    The IPO comprises a fresh issue of equity shares aggregating up to Rs480 crore and an offer for sale of up to 10 lakh equity shares by the selling shareholder. The price band has been fixed at Rs245-248 per share. At the upper end, the public issue would fetch Rs504 crore.


    Proceeds of the IPO will be utilized towards repayment of borrowings availed by the company besides purchasing medical equipment for existing, recently set-up as well as upcoming hospitals.


    Shalby also said it is looking at expansion in the eastern and North-eastern region.


    "We are looking for an opportunity for our presence in eastern region locations like Bhubaneshwar and Kolkata. However, nothing has been finalized yet," Shalby CEO Ravi Bhandari said on the sidelines of a roadshow for its maiden IPO.


    "In metros, we will expand with a super-speciality hospital but in an asset-light model," he said.


    Shalby has been expanding rapidly through tie-ups in which the hospital brand does not want to own reality to keep costs low. The company was also open to managing existing hospitals.


    A tie-up up with a Guwahati hospital for offering orthopaedic co-branded services like a shop-in-shop concept," Bhandari said.


    Currently, the hospital has nine operational hospitals and claimed to have 15 percent market share of all joint replacement surgeries conducted by private corporate hospitals in India in 2016.


    In the recent months, healthcare services firms Alkem Laboratories, Dr. Lal Pathlabs, Narayana Hrudayalaya, Thyrocare and Eris Lifesciences have tapped the primary market through IPO route.

    Alkem LaboratoriesDr Lal PathLabsequity sharesEris LifesciencesExpansionGuwahati hospitalinitial public offeringIPOmulti-specialty hospital chainNarayana HrudayalayaNational Stock ExchangeorthopaedicRavi BhandarishalbyShalby HospitalsShalby LtdsubscribedThyrocare
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok